Cortex Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 32 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Cortex Pharmaceuticals, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Cortex Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Cortex Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Cortex Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Cortex Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Cortex Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Cortex Pharmaceuticals, Inc.'s pipeline products

Reasons to buy

- Evaluate Cortex Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Cortex Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Cortex Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Cortex Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Cortex Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Cortex Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Cortex Pharmaceuticals, Inc. Snapshot 5
Cortex Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Cortex Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Cortex Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Cortex Pharmaceuticals, Inc. - Pipeline Products Glance 10
Cortex Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Cortex Pharmaceuticals, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Cortex Pharmaceuticals, Inc. - Drug Profiles 13
CX-1739 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
dronabinol 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
CX-1846 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
CX-1942 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
CX-2007 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
CX-2076 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
CX-929 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Cortex Pharmaceuticals, Inc. - Pipeline Analysis 22
Cortex Pharmaceuticals, Inc. - Pipeline Products by Target 22
Cortex Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 23
Cortex Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 24
Cortex Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 25
Cortex Pharmaceuticals, Inc. - Recent Pipeline Updates 26
Cortex Pharmaceuticals, Inc. - Dormant Projects 28
Cortex Pharmaceuticals, Inc. - Discontinued Pipeline Products 29
Discontinued Pipeline Product Profiles 29
CX-516 29
Cortex Pharmaceuticals, Inc. - Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables
Cortex Pharmaceuticals, Inc., Key Information 5
Cortex Pharmaceuticals, Inc., Key Facts 5
Cortex Pharmaceuticals, Inc. - Pipeline by Indication, 2014 7
Cortex Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2014 8
Cortex Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2014 9
Cortex Pharmaceuticals, Inc. - Phase II, 2014 10
Cortex Pharmaceuticals, Inc. - Phase I, 2014 11
Cortex Pharmaceuticals, Inc. - Preclinical, 2014 12
Cortex Pharmaceuticals, Inc. - Pipeline by Target, 2014 22
Cortex Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2014 23
Cortex Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2014 24
Cortex Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2014 25
Cortex Pharmaceuticals, Inc. - Recent Pipeline Updates, 2014 26
Cortex Pharmaceuticals, Inc. - Dormant Developmental Projects,2014 28
Cortex Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2014 29
Cortex Pharmaceuticals, Inc., Subsidiaries 30